Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 28 EP applications Michael Stierwald has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 17, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP13733645

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

IPC classification:
A61K 31/397, A61K 31/40, A61K 31/4025, A61K 31/404, A61P 25/00, A61P 29/00, A61P 35/00, C07D 205/04, C07D 207/16, C07D 207/22, C07D 209/18, C07D 209/42, C07D 209/94, C07D 403/04, C07D 471/04, C07D 471/10, C07D 487/04, C07D 487/10, C07D 498/10
Applicant:
Novartis AG
Agent:
Philippe Becker, Cabinet Becker & Associés
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13741412

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

IPC classification:
A61K 31/4355, A61K 31/436, A61K 31/4365, A61K 31/437, A61K 31/4375, A61K 31/519, A61P 25/02, A61P 25/04, A61P 35/00, C07D 211/60, C07D 211/66, C07D 471/04, C07D 491/048, C07D 491/056, C07D 495/04
Applicant:
Novartis AG
Agent:
Philippe Becker, Cabinet Becker & Associés
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13741446

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

IPC classification:
A61K 31/496, A61K 31/4985, A61K 31/551, A61P 25/02, A61P 25/04, A61P 35/00, C07D 241/04, C07D 243/08, C07D 403/04, C07D 413/04, C07D 413/06, C07D 487/04
Applicant:
Novartis AG
Agent:
Philippe Becker, Cabinet Becker & Associés
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13706360

AQUEOUS PHARMACEUTICAL COMPOSITION WITH ENHANCED STABILITY

IPC classification:
A61K 9/00, A61K 9/08, A61K 47/02, A61K 47/36, A61K 47/48
Applicant:
Novartis AG
Applicant:
Alcon Research, Ltd
Agent:
Günter Keller, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13723623

OPHTHALMIC COMPOSITIONS WITH IMPROVED DESSICATION PROTECTION AND RETENTION

IPC classification:
A61K 9/08, A61K 47/02, A61K 47/10, A61K 47/26, A61K 47/32, A61K 47/36
Applicant:
Novartis AG
Applicant:
Alcon Research, Ltd
Agent:
Oliver William Kingsbury, Elkington and Fife LLP
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13725348

AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING A BIOLOGIC THERAPEUTIC AGENT AND GUANIDINE OR A GUANIDINE DERIVATIVE AND AN INJECTION INCLUDING THE COMPOSITION

IPC classification:
A61K 9/00, A61K 47/18, A61K 47/26, C07K 16/18
Applicant:
Novartis AG
Agent:
Stephan Teipel, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15162722

LOW DOSE LIPOIC ACID PHARMACEUTICAL COMPOSITIONS AND METHODS

IPC classification:
A01N 37/00, A61K 31/19
Agent:
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13860388

FINAFLOXACIN SUSPENSION COMPOSITIONS

IPC classification:
A61K 9/00, A61K 31/5383
Applicant:
Alcon Research, Ltd
Agent:
Michael Best, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14707567

TOPICAL OCULAR ANALGESIC AGENTS

IPC classification:
A61K 9/00, A61K 31/53, A61K 47/40
Applicant:
Novartis AG
Agent:
Grünecker Patent- und Rechtsanwälte PartG mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15179323

CARBOXYVINYL POLYMER-CONTAINING NANOPARTICLE SUSPENSIONS

IPC classification:
A61K 9/10, A61K 9/14, A61K 31/165, A61K 47/02, A61K 47/32, A61K 47/36, A61P 27/02
Applicant:
Novartis AG
Applicant:
Alcon Research, Ltd
Agent:
Stephan Teipel, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15169431

METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN

IPC classification:
A61K 31/00, A61K 31/395, A61K 38/00, A61K 38/07, A61K 38/08, A61P 25/04, A61P 29/00, C07D 217/26, C07D 241/04, C07D 401/06, C07D 409/06, C07D 471/04, G01N 33/74
Applicant:
Novartis AG
Agent:
D Young & Co LLP
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15185071

OLOPATADINE FORMULATIONS FOR TOPICAL NASAL ADMINISTRATION

IPC classification:
A61K 9/00, A61K 9/08, A61K 31/335, A61K 47/02, A61K 47/18
Applicant:
Novartis AG
Agent:
Michael Best, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP13162570

Method of treatment or prophylaxis

IPC classification:
A61K 31/517, A61K 38/08, A61P 25/02, A61P 25/06, C07D 295/215
Applicant:
Novartis AG
Agent:
Kirk James Gallagher, D Young & Co LLP
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13162564

Method of treatment or prophylaxis

IPC classification:
A61K 31/517, A61K 38/08, A61P 25/02, A61P 25/06
Applicant:
Novartis AG
Agent:
Kirk James Gallagher, D Young & Co LLP
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP11740973

SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE

IPC classification:
C07D 217/26
Applicant:
Novartis AG
Agent:
Donald C. McNab, Marks & Clerk LLP
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14736523

TOPICAL AQUEOUS OPHTHALMIC COMPOSITIONS CONTAINING A 1H-INDOLE-1-CARBOXAMIDE DERIVATIVE AND USE THEREOF FOR TREATMENT OF OPHTHALMIC DISEASE

IPC classification:
A61K 9/00, A61K 9/08, A61K 31/506, A61K 31/519, A61K 47/02, A61K 47/10, A61K 47/18, A61K 47/26, A61K 47/32, A61K 47/34, A61K 47/38, A61P 27/02
Applicant:
Novartis AG
Agent:
Günter Keller, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14733730

USE OF A VEGF ANTAGONIST IN TREATING CHOROIDAL NEOVASCULARISATION

IPC classification:
A61K 38/17, A61K 39/395, A61K 47/48, A61P 27/02
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14733729

TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY

IPC classification:
A61K 38/18, A61K 41/00
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14733731

USE OF A VEGF ANTAGONIST IN TREATING MACULAR EDEMA

IPC classification:
A61K 38/17, A61K 39/395, A61K 47/48, A61P 27/02
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14741406

USE OF A VEGF ANTAGONIST IN TREATING CHORIORETINAL NEOVASCULAR AND PERMEABILITY DISORDERS IN PAEDIATRIC PATIENTS

IPC classification:
A61K 39/395, A61P 27/02, C07K 16/22
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14772237

METHOD FOR TREATING OTIC INFECTIONS AFTER TYMPANOSTOMY TUBE PLACEMENT

IPC classification:
A61K 9/00
Applicant:
Novartis AG
Agent:
Carpmaels & Ransford LLP
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP16156221

OPHTHALMIC COMPOSITION WITH A VISCOSITY ENHANCEMENT SYSTEM HAVING TWO DIFFERENT VISCOSITY ENHANCING AGENTS

IPC classification:
A61K 9/00, A61K 9/08, A61K 47/10, A61K 47/32, A61K 47/34, A61K 47/38
Applicant:
Novartis AG
Applicant:
Alcon Research, Ltd
Agent:
Stephan Teipel, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP16158101

HIGH CONCENTRATION OLOPATADINE OPHTHALMIC COMPOSITION

IPC classification:
A61K 9/00, A61K 9/08, A61K 31/335, A61K 47/10, A61K 47/32, A61K 47/40, A61P 27/14, C08L 5/16
Applicant:
Novartis AG
Applicant:
Alcon Research, Ltd
Agent:
Stephan Teipel, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15200360

SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE

IPC classification:
C07D 217/26
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15758583

LIPOIC ACID CHOLINE ESTER COMPOSITIONS AND METHODS OF USE

IPC classification:
A01N 43/26
Agent:
Maiwald Patentanwalts GmbH
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15791399

PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION

IPC classification:
A61K 31/5575, A61P 27/06
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis AG
Status:
Request for examination was made
EP15798609

STABLE PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY

IPC classification:
A61K 9/00, A61K 39/395, A61P 27/02
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis AG
Status:
Request for examination was made
EP15807721

METHODS FOR TREATING OCULAR DISEASES

IPC classification:
A61K 9/00, A61K 39/395, A61P 27/02
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis AG
Status:
Request for examination was made

Please Sign in to use this feature